Infant vegetable for Infants

Phase-Based Progress Estimates
University of Delaware, Newark, DE
Infants+2 More
Infant vegetable - Other
< 18
All Sexes
What conditions do you have?

Study Summary

This study evaluates the effect of different complementary foods on the gastrointestinal microbiota of exclusively human milk fed infants.

Eligible Conditions

  • Gastrointestinal Microbiota
  • Healthy Subjects (HS)
  • Infants

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Day 0, 4, 8, 12, 16, 20, 24, 28

Day 0
Change in gastrointestinal microbiota

Trial Safety

Trial Design

4 Treatment Groups

Infant cereal
1 of 4
Infant meat
1 of 4
Infant fruit
1 of 4
Infant vegetable
1 of 4
Active Control
Experimental Treatment

40 Total Participants · 4 Treatment Groups

Primary Treatment: Infant vegetable · No Placebo Group · N/A

Infant meat
Experimental Group · 1 Intervention: Infant meat · Intervention Types: Other
Infant fruit
Experimental Group · 1 Intervention: Infant fruit · Intervention Types: Other
Infant vegetable
Experimental Group · 1 Intervention: Infant vegetable · Intervention Types: Other
Infant cereal
ActiveComparator Group · 1 Intervention: Infant grain · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 0, 4, 8, 12, 16, 20, 24, 28

Trial Background

Prof. Jill Trabulsi, Associate Professor
Principal Investigator
University of Delaware
Closest Location: University of Delaware · Newark, DE
2007First Recorded Clinical Trial
1 TrialsResearching Infants
41 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a woman who was born vaginally.
You have a parent/legal guardian who is at least 18 years old.
The infant is not yet consuming solid foods.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.